39 search results for Prolactin
| # | SuperPathway Name | Genes Count | Relevance Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prolactin Signaling | 432 | 2.386 | |||||||
|
||||||||||
| 2 | Prolactin signaling pathway | 2 | 1.901 | |||||||
|
||||||||||
| 3 | Growth hormone receptor signaling | 29 | 1.366 | |||||||
|
||||||||||
| 4 | JAK-STAT signaling in the regulation of Beta-cells | 35 | 0.665 | |||||||
|
||||||||||
| 5 | PI3K-Akt signaling pathway | 390 | 0.665 | |||||||
|
||||||||||
| 6 | TGF-Beta Pathway | 653 | 0.665 | |||||||
|
||||||||||
| 7 | Metabolism of proteins | 1970 | 0.665 | |||||||
|
||||||||||
| 8 | Cytokine Signaling in Immune system | 732 | 0.665 | |||||||
|
||||||||||
| 9 | GPCR downstream signalling | 710 | 0.665 | |||||||
|
||||||||||
| 10 | Signaling by ERBB4 | 70 | 0.665 | |||||||
|
||||||||||
| 11 | Class A/1 (Rhodopsin-like receptors) | 556 | 0.665 | |||||||
|
||||||||||
| 12 | Signaling events mediated by PTP1B | 46 | 0.665 | |||||||
|
||||||||||
| 13 | Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) | 32 | 0.665 | |||||||
|
||||||||||
| 14 | Signal Transduction | 2590 | 0.665 | |||||||
|
||||||||||
| 15 | Innate Immune System | 2025 | 0.665 | |||||||
|
||||||||||
| 16 | Transport of inorganic cations/anions and amino acids/oligopeptides | 728 | 0.471 | |||||||
|
||||||||||
| 17 | Akt Signaling | 682 | 0.471 | |||||||
|
||||||||||
| 18 | NF-kappaB Signaling | 327 | 0.471 | |||||||
|
||||||||||
| 19 | PAK Pathway | 686 | 0.471 | |||||||
|
||||||||||
| 20 | Ovarian infertility | 36 | 0.471 | |||||||
|
||||||||||
| 21 | Transcription Ligand-dependent activation of the ESR1/SP pathway | 51 | 0.471 | |||||||
|
||||||||||
| 22 | MIF Mediated Glucocorticoid Regulation | 681 | 0.471 | |||||||
|
||||||||||
| 23 | Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics | 20 | 0.471 | |||||||
|
||||||||||
| 24 | Cellular responses to stimuli | 802 | 0.471 | |||||||
|
||||||||||
| 25 | Prostaglandin synthesis and regulation | 56 | 0.471 | |||||||
|
||||||||||
| 26 | ERK Signaling | 1185 | 0.471 | |||||||
|
||||||||||
| 27 | Vesicle-mediated transport | 673 | 0.471 | |||||||
|
||||||||||
| 28 | Adipogenesis | 131 | 0.471 | |||||||
|
||||||||||
| 29 | Primary ovarian insufficiency | 170 | 0.471 | |||||||
|
||||||||||
| 30 | Miscellaneous transport and binding events | 26 | 0.471 | |||||||
|
||||||||||
| 31 | 2q37 copy number variation syndrome | 88 | 0.471 | |||||||
|
||||||||||
| 32 | Transport to the Golgi and subsequent modification | 304 | 0.471 | |||||||
|
||||||||||
| 33 | Unfolded Protein Response (UPR) | 94 | 0.471 | |||||||
|
||||||||||
| 34 | EV release from cardiac cells and their functional effects | 7 | 0.471 | |||||||
|
||||||||||
| 35 | Glucocorticoid receptor regulatory network | 77 | 0.471 | |||||||
|
||||||||||
| 36 | wtCFTR and delta508-CFTR traffic / Generic schema (norm and CF) | 135 | 0.471 | |||||||
|
||||||||||
| 37 | Validated nuclear estrogen receptor alpha network | 65 | 0.471 | |||||||
|
||||||||||
| 38 | COPII-mediated vesicle transport | 70 | 0.471 | |||||||
|
||||||||||
| 39 | RNA Polymerase I Promoter Opening | 509 | 0.471 | |||||||
|
||||||||||